Palisade Bio Balance Sheet Health
Financial Health criteria checks 6/6
Palisade Bio has a total shareholder equity of $6.6M and total debt of $235.0K, which brings its debt-to-equity ratio to 3.6%. Its total assets and total liabilities are $9.3M and $2.7M respectively.
Key information
3.6%
Debt to equity ratio
US$235.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.05m |
| Equity | US$6.61m |
| Total liabilities | US$2.73m |
| Total assets | US$9.34m |
Recent financial health updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07Financial Position Analysis
Short Term Liabilities: PALI's short term assets ($8.9M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: PALI's short term assets ($8.9M) exceed its long term liabilities ($47.0K).
Debt to Equity History and Analysis
Debt Level: PALI has more cash than its total debt.
Reducing Debt: PALI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PALI has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: PALI is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:37 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Palisade Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jason McCarthy | Maxim Group |